Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 894416 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)

Trial Profile

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 894416 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Jul 2018

At a glance

  • Drugs BI 894416 (Primary)
  • Indications Unspecified
  • Focus Adverse reactions; First in man
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 09 Jul 2018 Planned number of patients changed from 80 to 76.
    • 05 Jun 2018 Planned End Date changed from 12 Jun 2018 to 3 Sep 2018.
    • 05 Jun 2018 Planned primary completion date changed from 12 Jun 2018 to 3 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top